Topics

vaccine dynamics

 

Vaccine dynamics is the study of how vaccination strategies and behaviors interact with the spread of infections diseases within a population.  

Biodistribution is a method of tracking where compounds of interest travel and where they are retained in the organs and tissues of an experimental animal or human subject receiving a vaccine; the biodistribution of a vaccine.

vaccines
2.4 Nonclinical Overview AZD1222
2.5 Clinical Overview: AZD1222 Marketing Authorisation Application - Primary Analysis (Data Cut-off 07 December 2020)
A Case Report of Acute Lymphoblastic Leukaemia (ALL)/Lymphoblastic Lymphoma (LBL) Following the Second Dose of Comirnaty®: An Analysis of the Potential Pathogenic Mechanism Based on of the Existing Literature
A cautionary note: Toxicity of polyethylene glycol 200 injected intraperitoneally into mice
A Closer Look at N1-methylpseudouridine in the Modified mRNA Injectables
A web‑based genome‑wide association study reveals the susceptibility loci of common adverse events following COVID‑19 vaccination in the Japanese population
An Independent Analysis of the Manufacturing and Quality Issues of the BNT162b BioNTech/Pfizer Quasi-vaccine based on the European Medicines Agency’s Public Assessment Report (EPAR)
Anaphylaxis-Induced Acute Coronary Syndrome Following Covid-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches
Assessment report: COVID-19 Vaccine Moderna
Autoimmune and Neoplastic Outcomes After the mRNA Vaccination: The Role of T Regulatory Cell Responses
Biodistribution of mRNA COVID-19 vaccines in human breast milk
BioNTech RNA-Based COVID-19 Injections Contain Large Amounts Of Residual DNA Including An SV40 Promoter/Enhancer Sequence
Cationic compounds used in lipoplexes and polyplexes for gene delivery
Comirnaty Facts: Mechanisms of action and damage potential
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1
Current state of knowledge on the excretion of mRNA and spike produced by anti-COVID-19 mRNA vaccines; possibility of contamination of the entourage of those vaccinated by these products
Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies Detected 1 Year After BNT162b2 Vaccination in Children
Differences in Vaccine and SARS-CoV-2 Replication Derived mRNA: Implications for Cell Biology and Future Disease
Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria
First case of postmortem study in a patient vaccinated against SARS-CoV-2
Form S-1 Registration Statement Under the Securities Act of 1933: BioNTech SE
Form S-1 Registration Statement Under the Securities Act of 1933: Moderna, Inc.
Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity
Graphene and graphene oxide as nanomaterials for medicine and biology application
Graphene and the Immune System: A Romance of Many Dimensions
How Bad is My Batch? Batch codes and associated deaths, disabilities and illnesses for Covid 19 Vaccines
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line
Long Term Follow-Up After Administration of Human Gene Therapy Products Guidance for Industry
Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination
mRNA Platform: Enabling Drug Discovery & Development
mRNA, Nanolipid Particles and PEG: A Triad Never Used in Clinical Vaccines is Going to Be Tested on Hundreds of Millions of People
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Nonclinical Evaluation Report: BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATY)
Pathology Deterioration in a Pure β-zero Thalassemia Heterozygote After mRNA COVID-19 Vaccination: A Case Report and Literature Review
Pfizer/BioNTech’s COVID-19 modRNA Vaccines: Dangerous Genetic Mechanism of Action Released before Sufficient Preclinical Testing
Potential adverse effects of nanoparticles on the reproductive system
Potential health risks of mRNA-based vaccine therapy: A hypothesis
Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
Real-Time Self-Assembly of Stereomicroscopically Visible Artificial Constructions in Incubated Specimens of mRNA Products Mainly from Pfizer and Moderna: A Comprehensive Longitudinal Study
Research Letter: Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk
Response: Ed Humpherson to Norman Fenton, Martin Neil, Clare Craig and Scott McLachlan: ONS Deaths by Vaccination Status statistics
Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues
Safe Nanoparticles: Are We There Yet?
SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination
SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells
Session 86 of the Corona Investigative Committee
Statement by Dr. Richard Urso
Statement by Professor Christian Perronne at Parliamentary Hearing in Luxemburg
Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2
1471